Skip to contentR
Rapport Therapeutics, Inc.
R
RAPPRapport Therapeutics, Inc. RAPP Q2 2024 · Rapport Therapeutics, Inc. · ThalerReleased Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0000950170-24-093334
Q2 2024 · 10-Q
Revenue—
Net Income-$18.12M-$18.12MN/M vs Q2 2023N/M vs Q1 2024 EPS Diluted-$1.70-$1.70
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rapport Therapeutics, Inc. · CIK 2012593 · Engraved from SEC EDGAR
N/M vs Q1 2024
Operating Income-$20,800,000N/M Operating Cash Flowderived-$16,352,000— Free Cash Flowderived-$17,319,000— ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end
12.3% from the close of Aug 6, 2024 to the close of Aug 8, 2024, the first after the release.
before the open$21.16$18.56 Jul 1Aug 8Sep 12